16 Sep 2020

 

Mereo’s Etigilimab antibody program featured in Nature Biotechnology review of TIGIT-targeting’s potential to be the next validated cancer checkpoint

 

Link to article: 

Dolgin, E. Antibody engineers seek optimal drug targeting TIGIT checkpoint. Nat Biotechnol 38, 1007–1009 (2020).